๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Ipilimumab extends survival in advanced melanoma

Book ID
120842268
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2008
Weight
139 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Nivolumab plus Ipilimumab in Advanced Me
Nivolumab plus Ipilimumab in Advanced Melanoma
โœ Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Ri ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 646 KB
Nivolumab plus Ipilimumab in Advanced Me
Nivolumab plus Ipilimumab in Advanced Melanoma
โœ Wolchok, Jedd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Ri ๐Ÿ“‚ Article ๐Ÿ“… 2013 ๐Ÿ› Massachusetts Medical Society ๐ŸŒ English โš– 646 KB

## BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyteassociated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis of t